Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock
June 18 2014 - 9:05PM
Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the
pricing of its underwritten public offering of 4,000,000 shares of
its common stock at a price to the public of $30.50 per share
pursuant to a registration statement filed with the Securities and
Exchange Commission (SEC). All of the shares in the offering are to
be sold by Revance. In addition, the underwriters of the offering
have been granted a 30-day option to purchase up to an additional
600,000 shares from Revance. The offering is expected to close on
June 24, 2014, subject to customary closing conditions.
Cowen and Company and Piper Jaffray are acting as joint
book-running managers for the offering, with BMO Capital Markets
and William Blair acting as co-managers.
The offering will be made only by means of a prospectus, copies
of which may be obtained by contacting Cowen and Company, LLC, c/o
Broadridge Financial Services, Attention: Prospectus Department,
1155 Long Island Avenue, Edgewood, NY 11717, Telephone:
631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800
Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone:
800-747-3924, Email: prospectus@pjc.com.
A registration statement relating to these securities has been
filed with the SEC and was declared effective by the SEC on June
18, 2014. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company that develops
botulinum toxin products for use in aesthetic and therapeutic
indications. Revance has developed a platform technology,
TransMTS®, which enables local, targeted delivery of botulinum
toxin and other potent macromolecules across skin without patches,
needles or other invasive procedures.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to Revance's
expectations regarding the completion of the public offering.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include, without limitation, risks
and uncertainties related to whether or not Revance will be able to
raise capital through the sale of shares of common stock, the final
terms of the public offering, market and other conditions, the
satisfaction of customary closing conditions related to the public
offering and the impact of general economic, industry or political
conditions in the United States or internationally. There can be no
assurance that Revance will be able to complete the public offering
on the anticipated terms, or at all. Revance will need to raise
additional capital to fund its operations and may be unable to
raise capital when needed, which would force Revance to delay,
reduce or eliminate its product development programs or
commercialization efforts. You should not place undue reliance on
these forward-looking statements, which apply only as of the date
of this press release. Additional risks and uncertainties
relating to the public offering, Revance and its business can be
found under the heading "Risk Factors" in the prospectus included
in Revance's Registration Statement on Form S-1 (File No.
333-196582), initially filed with the SEC on June 6, 2014, as
amended. Revance expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
CONTACT: Westwicke Partners, Investor Relations
Lynn Pieper
415-202-5678
lynn.pieper@westwicke.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Oct 2023 to Oct 2024